INTRODUCTION
Prematurity continues to be the leading cause of infant morbidity and mortality in the United States. 1 While only 11% of all pregnancies result in preterm birth, the majority of neonatal morbidity and deaths are related to preterm births. 2, 3 The strict definition of premature birth includes all births before 37 weeks gestation, but most of the neonatal mortality and morbidity associated with prematurity results from births occurring before 32 weeks gestation (2% of all births). 4 Approximately one-third of preterm births occur because it becomes necessary to induce delivery in conditions such as pre-eclampsia, antepartum hemorrhage or presumed fetal growth restriction. 5 However, considerable effort is spent attempting to stop spontaneous preterm birth from preterm labor or preterm premature rupture of membranes.
Preterm labor is likely caused by many etiologic factors and therefore targeted treatment is difficult. 6 Many pharmacologic agents have been used to inhibit labor. These include B-adrenergic agonists (terbutaline, Ritodrine, albuterol etc.), magnesium sulfate, oxytocin antagonist, calcium channel blockers, and prostaglandin inhibitors (aspirin, indomethacin). 7 Prostaglandins affect the uterus by enhancing production of gap junctions in the myometrium and by stimulating the influx of intracellular calcium and the release of calcium from the sarcoplasmic reticulum. 8 The increase in intracellular calcium activates the myosin light chain kinase and results in muscle contractions. 8 Increased levels of prostaglandins have been found in the plasma and amniotic fluid of normal term laboring patients.
Prostaglandin metabolites are higher in preterm delivered patients. 4 Prostaglandin inhibitors act by inhibiting the enzyme cyclooxygenase. 8 Cyclooxygenase is found in high concentrations in the myometrium and acts by converting arachidonic acid into prostaglandin G2. All subsequent prostaglandins result from this initial step. Aspirin causes an irreversible inhibition of cyclooxygenase by acetylation. Indomethacin competes with arachidonic acid for cyclooxygenase and thus prevents the synthesis of prostaglandins.
Indomethacin has been used as a tocolytic since the 1970s. 9 Zuckerman et al. 10 reported that indomethacin was successful in stopping uterine contractions in 40 of 50 patients, with a delay of up to 7 weeks in some cases and with no apparent ill maternal side effects. Niebyl et al. 11 confirmed these results in the first randomized double-blind placebo controlled trial. Since that time, several studies have reported various success rates and various side effects with indomethacin use. [12] [13] [14] Based on a critical analysis of randomized controlled trial data, Higby et al. 15 suggested that indomethacin is the most efficacious tocolytic medication.
There remains much controversy concerning possible deleterious fetal and neonatal effects of tocolysis with indomethacin. 16 Norton et al. 17 in a matched, retrospective cohort study of infants exposed to indomethacin who were delivered at or before 30 weeks gestation, reported that antenatal indomethacin exposure was associated with an increased incidence of necrotizing enterocolitis (NEC), Grades II to IV intraventricular hemorrhage (IVH), neonatal oliguria, and patent ductus arteriosus (PDA). Similarly, Major et al. 18 concluded that treatment with indomethacin occurring within 24 hours of delivery and of at least 48 hours duration resulted in an increased incidence in NEC in exposed low birth weight neonates. In contrast, Gardner et al. 19 performed a matched cohort study of 124 infants between 24 and 31 4/7 weeks gestation. They found no increased risk of neonatal complications associated with indomethacin use.
In October 1995, our Maternal Fetal Medicine Division instituted a change in its protocol for the treatment of women diagnosed with preterm labor. Tocolytic treatment was employed for women between 24 and 34 weeks gestation with regular uterine contractions and documented cervical change. After a review of the available literature concerning the efficacy of tocolytics, it was decided that indomethacin would be the first-line tocolytic used. Previously, indomethacin was only used after treatment failure with terbutaline or magnesium sulfate. At the time of the protocol change, outcomes of neonates exposed to antenatal indomethacin were monitored. The purpose of this study is to compare the neonatal outcomes of very low birth weight infants exposed to antenatal indomethacin as a first-line tocolytic with those not exposed to indomethacin tocolysis.
MATERIALS AND METHODS
After obtaining IRB approval, we performed a retrospective cohort analysis of all newborn infants weighing less than 1500 g (VLBW) who were delivered at our University hospital over a 5-year period (1995 to 2000). We compared all VLBW infants who were exposed to antenatal indomethacin as a treatment for preterm labor with those VLBW infants who were not exposed to antenatal indomethacin, but may have been exposed to other tocolytic agents. We used our center's component of the NICHD Neonatal Research Network's Generic Data Base. The NICHD Neonatal Research Network's Generic Data Base has been described in detail previously. 20 From the database, we identified 85 VLBW who were exposed to antenatal indomethacin as a treatment for preterm labor. We abstracted data concerning neonatal complications such as neonatal death and severe IVH (Grades III to IV), NEC, and PDA, as well as selected maternal data. These data were compared to those VLBW infants who were not exposed to antenatal indomethacin. Subsequently, the medical records of all the mothers who received antenatal indomethacin for tocolysis and who then delivered a VLBW infant were reviewed. Further information was abstracted including the total indomethacin dose and the period of time between the last dose of indomethacin and delivery.
For the purposes of our study the diagnosis of NEC was made when an infant met Bell's stage 2 criteria. 21 Severe IVH was defined as Grade 3/4 hemorrhage as described by Papile et al. 22 The data were analyzed first using univariate analysis (Fisher's exact test). An alpha of 0.05 was considered statistically significant. A multivariate analysis, using stepwise logistic regression, was then performed to control for potential confounding factors including exposure to antenatal corticosteroids, maternal hypertension/preeclampsia, and birth weight. Odds ratios and 95% confidence intervals were obtained from the logistic regression.
Preterm labor was defined as a regular uterine contraction, every 5 to 10 minutes or six to 10 contractions in 1 hour, associated with progressive cervical effacement or dilation in women whose pregnancies were of less than 34 weeks gestation. Requirements for consideration of labor suppression included absence of fetal maturity with a live fetus and absence of maternal or fetal conditions dictating delivery. The women who received tocolysis were hydrated with 1000 cm 3 Ringers Lactate solution for over 30 to 60 minutes, and then maintained with D5 1 2 NS at a rate of 100 cm 3 /hour. Maternal vital signs, continuous fetal heart monitoring and uterine contractions were recorded. Digital examinations were kept to a minimum frequency.
The women were given an IV bolus of 6 g of magnesium sulfate over 15 minutes followed by a continuous infusion of 2 to 3 gm/ hour. Deep tendon reflexes and oxygen saturation were recorded every hour. After confirmation of normal amniotic fluid volume by ultrasound, the women then received indomethacin 50 mg PO or a 100 mg indomethacin rectal suppository. Maintenance indomethacin consisted of 50 mg PO or PR every 6 hours for a total not exceeding 48 hours or a total dose of 400 mg. At 2 hours after the administration of the first dose of indomethacin, the magnesium sulfate IV drip was stopped.
Indomethacin was defined as the first-line tocolytic because it was the main agent used for the first 48 hours. Magnesium sulfate was given for less than 4 hours and only for the time it took to perform an ultrasound to evaluate amniotic fluid volume and receive indomethacin from the pharmacy. In the analysis, the use of magnesium sulfate was controlled. For the patients in the control group, magnesium sulfate was the most commonly used tocolytic therapy. The patients were also given Betamethasone (12 mg intramuscularly) at the time of diagnosis of preterm labor and for a second time 12 hours later. Women receiving IV tocolytics prior to transfer to our medical center received indomethacin upon arrival, and within 2 hours they were weaned off the IV medication and switched to the indomethacin protocol. Surfactant therapy was administered to infants who had roentenographic evidence of surfactant deficiency and required assisted ventilation with a FiO 2 requirement Z0.40.
RESULTS
Of the 573 VLBW infants born during the study period, the records of 549 were available for review: 85 who were exposed to indomethacin and 464 who were not. Of the 85 infants who were exposed to indomethacin, the mean dosage was 296 mg with a range of 50 to 400 mg. In all, 40 of the 85 exposed infants received the maximum dose. The demographic characteristics of both the indomethacin and the controlled groups are summarized in Table 1 .
There were no significant differences between the two groups in maternal age, mode of delivery, fetal sex, intrauterine growth restriction (IUGR), preterm premature rupture of membranes (PPROM), chorioamnionitis, or surfactant use. There was a significant difference in gestational age and mean birth weights with the indomethacin group on average being delivered earlier and having smaller birth weights. A total of 90% of the indomethacin-exposed infants received antenatal steroids compared to 68% in the nonexposed group.
The univariate analysis is summarized in Table 2 . There was no significant difference in the incidence of NEC or PDA between the two groups. Neonatal deaths and severe IVH were significantly more likely in those infants exposed to indomethacin.
Due to concerns of confounders, particularly the earlier gestational age and the lower mean birth weights in the indomethacin group, a multivariate analysis using logistic regression was performed. The logistic regression controlled for gestational age, birth weight, maternal hypertension, and antenatal corticosteroid use. In the multivariate analysis, antenatal indomethacin treatment was not significantly associated with an increased risk of NEC or PDA. There was a nonsignificant increase in the risk of neonatal death with an odds ratio of 1.37 with confidence intervals of 0.71 to 2.64. After controlling for the confounders, severe IVH remained significantly more likely in those infants exposed to antenatal indomethacin. The odds ratio for severe IVH was 2.7 with confidence interval of 1.17 to 6.36.
SIGNIFICANCE
Our study adds to the evidence that caution should be used when employing indomethacin for tocolysis. The results of our study are mixed. We, like Norton et al., 17 found that antenatal indomethacin was associated with an increased rate of severe IVH. However, unlike Major et al., 18 we did not find an increased rate of NEC or PDA.
The weaknesses of our study are similar to the previous reports. It is a retrospective cohort study and thus subject to confounding and bias. The population in our study that received indomethacin was of an earlier gestational age and of a lower birth weight. However, using logistic regression techniques, the increased risk of severe IVH persisted even when controlling for birth weight and gestational age.
Vermillion et al. 23 reported a retrospective case-control study matching 75 infants who were exposed to antenatal indomethacin with 150 controls. In their study, they did not find an increased incidence of severe IVH, NEC, or PDA. There were no significant differences in neonatal outcomes between the indomethacinexposed and the control groups.
What makes our study unique compared with the other previous retrospective reviews is that our institution was the first to report its experience after using indomethacin as a first-line tocolytic. This potentially controlled for physician bias as previous reports used indomethacin as a second-line tocolytic at the discretion of the attending physician. Given that all 85 infants who were exposed to indomethacin received it as a first-line tocolytic, this should have removed any judgmental bias by the attending physician.
Protective effects of antenatal corticosteroids have been previously described; 24, 25 however, we found no significant benefit. In fact, the increased incidence of severe IVH in the indomethacin group occurred despite 90% of the indomethacin group receiving antenatal corticosteroids.
The possible mechanism of action of indomethacin as a factor in the development of IVH has been previously described. 16 It has been noted that with maternal indomethacin use, the fetal middle cerebral artery pulsatility index increases in association with ductal constriction and tricuspid regurgitation. Moreover, indomethacin inhibits platelet aggregation. Perhaps the combination of fluctuations in intracranial pressure during active labor with platelet dysfunction contributes to the increased risk of IVH after antenatal use of indomethacin. The increased incidence of postnatal PDA after antenatal indomethacin exposure may also play a role in the development of IVH. Furthermore, rapid postnatal volume expansion, in the face of indomethacin-induced oliguria, may increase cerebral capillary pressure. All of these mechanisms may individually or collectively lead to an increase in the incidence of IVH found in preterm infants after antenatal use of indomethacin or other nonsteroidal anti-inflammatory drugs. 16 Prematurity remains the number one problem facing obstetrics in the United States. 2 For this reason, an effective tocolytic that would stop preterm labor is highly desirable. The end point of a tocolytic should not be preventing preterm birth but rather preventing the mortality and morbidity associated with preterm birth. Before widespread adoption of indomethacin as the first-line tocolytic can occur, a randomized control trial needs to be performed with a primary end point being the incidence of neonatal mortality and morbidity. If indeed, as discussed by Higby et al. 15 indomethacin is the most effective tocolytic presently available, then the potential benefits to the neonate of prolonging a preterm pregnancy and thus lessening the potential morbidity associated with preterm births may outweigh any untoward side effects caused by the medication. Moreover, while the controversy concerning indomethacin persists, frank conversations with patients and their families concerning the potential benefits and risks of antenatal indomethacin would seem prudent.
